In a report released on April 2, Michael Cherny from Leerink Partners maintained a Buy rating on McKesson (MCK – Research Report), with a price ...

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded ...

Leerink Partners analyst Faisal Khurshid reiterated a Hold rating on Nurix Therapeutics (NRIX – Research Report) on April 2. The company’s ...

Research analysts at Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for shares of Maze Therapeutics in ...

Leerink Partners upgraded shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) from a market perform rating to an outperform rating in a research report report published on Wednesday, MarketBeat ...

Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (NasdaqCM:EQ) from Outperform ...

Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector ...

Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Leerink Partners Global Healthcare Conference in Miami, Florida. Dr. Brady’s ...

will present at the Leerink Partners Global Biopharma Conference in Miami, FL on Monday, March 10, 2025, at 3:00 p.m. ET. A live webcast of the presentation may be accessed via the Investors ...

today announced that management is scheduled to present at the 2025 Leerink Partners Global Healthcare Conference on Tuesday, March 11th at 3:00 p.m. ET. An audio webcast of the presentation can ...

It was previously corrected to change the brokerage's name to Leerink Partners, not Jefferies, in paragraph 4) Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's ...